Eli Lilly-AtaiBeckley deal requires antitrust approval in Australia, Germany
MLex Summary: Eli Lilly's proposed $3.8 billion acquisition of AtaiBeckley will require antitrust approval in Australia and Germany, according to a securities filing. "In addition to the requirements under the HSR...To view the full article, register now.
Already a subscriber? Click here to view full article